Advagene Biopharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Selling, General & Admin	20.59	20.55	20.12	19.77	21.75	Upgrade
Research & Development	50.33	50.27	73.22	100.04	72.68	Upgrade
Operating Expenses	70.92	70.82	93.34	119.81	94.43	Upgrade
Operating Income	-70.92	-70.82	-93.34	-119.81	-94.43	Upgrade
Interest Expense	-0.18	-0.15	-0.04	-0.08	-0.12	Upgrade
Interest & Investment Income	2.6	1.7	1.02	1.31	1.53	Upgrade
Currency Exchange Gain (Loss)	0.2	-0.2	0.25	0.2	0.12	Upgrade
Other Non Operating Income (Expenses)	-	0.06	-	-	0.16	Upgrade
EBT Excluding Unusual Items	-68.29	-69.42	-92.11	-118.38	-92.74	Upgrade
Gain (Loss) on Sale of Investments	-	-	-	-	0.05	Upgrade
Pretax Income	-68.29	-69.42	-92.11	-118.38	-92.69	Upgrade
Net Income	-68.29	-69.42	-92.11	-118.38	-92.69	Upgrade
Net Income to Common	-68.29	-69.42	-92.11	-118.38	-92.69	Upgrade
Shares Outstanding (Basic)	59	55	50	49	49	Upgrade
Shares Outstanding (Diluted)	59	55	50	49	49	Upgrade
Shares Change (YoY)	8.64%	8.47%	2.14%	1.23%	9.95%	Upgrade
EPS (Basic)	-1.15	-1.27	-1.83	-2.40	-1.90	Upgrade
EPS (Diluted)	-1.15	-1.27	-1.83	-2.40	-1.90	Upgrade
Free Cash Flow	-65.64	-71.12	-77.7	-109.56	-67.7	Upgrade
Free Cash Flow Per Share	-1.10	-1.30	-1.54	-2.22	-1.39	Upgrade
EBITDA	-70.62	-70.52	-89.32	-115.25	-89.24	Upgrade
D&A For EBITDA	0.3	0.31	4.02	4.56	5.19	Upgrade
EBIT	-70.92	-70.82	-93.34	-119.81	-94.43	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.